We have recently assembled a comprehensive list detailing the 12 Most Undervalued Dow Stocks to Buy According to Analysts. Notably, Merck & Co., Inc. stands out among them.
Positioned as a global healthcare powerhouse, Merck & Co., Inc. (NYSE:MRK) has earned recognition for being one of the most undervalued stocks. The company’s portfolio encompasses pharmaceuticals, vaccines, biologics, and products for animal health, presenting a well-rounded investment opportunity.
A pivotal update includes the recent FDA approval of the KEYTRUDA QLEX on September 19, 2025. This new subcutaneous injectable formulation represents a significant advancement in the administration of the company’s flagship cancer treatment, Keytruda. Patients can now receive this injection in one to two minutes— a substantial reduction from the 30-minute intravenous infusion method— thereby improving both patient comfort and clinical efficiency. Projections anticipate that this new formulation could secure 30-40% of the Keytruda user base within two years, solidifying Merck’s market dominance even with the looming competition from biosimilars.
Further enhancing its position in the healthcare landscape, Merck & Co., Inc. (NYSE:MRK) has garnered a positive opinion from the European Medicines Agency regarding ENFLONSIA (clesrovimab), an innovative RSV prevention treatment for infants. This would mark the first weight-independent preventive option for RSV available to European infants, which addresses a critical healthcare gap.
Image Credit: 360b / Shutterstock.com
From a financial perspective, Merck & Co., Inc. (NYSE:MRK) has reported impressive results for the second quarter of 2025. Analysts consistently underscore the strengths of its vaccine division, its animal health products, and its pioneering oncology therapies, particularly the combination therapies involving Keytruda. Moreover, the company is in the process of developing several novel drug candidates, such as raludotatug deruxtecan, which has recently been designated as a Breakthrough Therapy by the FDA for the treatment of platinum-resistant ovarian and related cancers, expediting availability for patients facing significant medical challenges.
While recognizing Merck & Co., Inc.’s potential as an investment, it’s important to note that certain AI stocks may provide more attractive upside potential with reduced downside risk. If you are in search of an extremely undervalued AI stock poised to benefit from current economic trends, we invite you to check out our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
This rewritten article maintains the original structure and key points while integrating unique content suitable for a WordPress platform.
